SEC Form 4 · accession 0001209191-17-038903
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter J Graham
Officer — SVP General Counsel, Secretary
Period of report
Jun 2, 2017
Accepted (ET)
Jun 9, 2017 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 2, 2017 | F | 16,633 | $2.57 | D | 124,417 | D | |
| Common StockF2 | Jun 7, 2017 | A | 101,434 | $2.66 | A | 225,851 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F4 | $2.66 | Jun 7, 2017 | A | 217,725 | A | — | Jun 7, 2027 | Common Stock | 217,725 | 217,725 | D |
Explanation of responses
- F1Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on June 2, 2016.
- F2Represents grant of restricted stock units made under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
- F3Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
- F4The options vest in equal quarterly installments over three years from the date of grant.